search
Back to results

The Role of Nitric Oxide in Cognition in Schizophrenia (NOC)

Primary Purpose

Schizophrenia, Psychotic Disorders

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Glyceryl Trinitrate
Placebo
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia focused on measuring Nitric Oxide, Cognition

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-40 years of age
  • Patients undergoing an acute psychotic episode (defined as score > 4 on question P1 of the PANSS positive subscale) requiring full-time hospitalisation according to clinical referral by the relevant mental health service
  • Demonstrates capacity and willing to give informed consent
  • Female participants willing to have a pregnancy test before treatment
  • Currently unmedicated with antipsychotic medication

Exclusion Criteria:

  • Major physical illness
  • Prior history of intolerance to glyceryl trinitrate
  • Homicidal or suicidal
  • Pregnant or breast feeding

Sites / Locations

  • South London and Maudsley

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Glyceryl Trinitrate

Placebo

Arm Description

Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.

The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.

Outcomes

Primary Outcome Measures

The emotionally salient version of the Jumping to Conclusions (JTC) task

Secondary Outcome Measures

The Hopkins Verbal Learning Task - Revised, immediate recall
Positive and negative syndrome scale (PANSS) (videotaped)
The Bond-Lader Visual Analog Scales

Full Information

First Posted
September 15, 2016
Last Updated
August 12, 2019
Sponsor
King's College London
Collaborators
South London and Maudsley NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02906553
Brief Title
The Role of Nitric Oxide in Cognition in Schizophrenia
Acronym
NOC
Official Title
The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
September 2016 (undefined)
Primary Completion Date
April 2019 (Actual)
Study Completion Date
April 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
South London and Maudsley NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the role of the Nitric Oxide system in cognition in patients with schizophrenia. Participants will be randomised to 2 equal groups and receive either the Nitric Oxide donor molecule glyceryl trinitrate, or a placebo. Performance on several cognitive tasks will be assessed.
Detailed Description
Nitric oxide [NO] is a gaseous neurotransmitter substance found in the brain. Nitric oxide is integrated with the glutamate system. Glutamate has received considerable attention as an important factor in the cognitive distortions and cognitive impairments that underlie schizophrenia. Deficits in glutamate in schizophrenia may impact upon cognition via the NO system, as glutamate receptors signal by way of NO. Here the investigators aim to extend knowledge of glutamate-NO systems by directly examining the role of NO in cognition in patients with psychosis. We aim to assess the role of the NO system in cognition, downstream of glutamate and before patients are started on any anti-psychotic medication which perturb brain neurochemistry. The primary outcome measure is change in a particular style of cognition referred to as 'jumping to conclusions' following the administration of a potent Nitric Oxide donor molecule [glyceryl trinitrate (GTN)], under placebo-controlled, double-blind conditions. This will shed light on the direct role of NO in cognition in psychosis, beyond the glutamate system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Psychotic Disorders
Keywords
Nitric Oxide, Cognition

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Glyceryl Trinitrate
Arm Type
Experimental
Arm Description
Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
Intervention Type
Drug
Intervention Name(s)
Glyceryl Trinitrate
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
The emotionally salient version of the Jumping to Conclusions (JTC) task
Time Frame
Change in performance from baseline to Day1, Day 2, Day 3, Day 7
Secondary Outcome Measure Information:
Title
The Hopkins Verbal Learning Task - Revised, immediate recall
Time Frame
Change from baseline to Day1, Day 2, Day 3, Day 7
Title
Positive and negative syndrome scale (PANSS) (videotaped)
Time Frame
Change from baseline to Day1, Day 2, Day 3, Day 7
Title
The Bond-Lader Visual Analog Scales
Time Frame
Change from baseline to Day1, Day 2, Day 3, Day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-40 years of age Patients undergoing an acute psychotic episode (defined as score > 4 on question P1 of the PANSS positive subscale) requiring full-time hospitalisation according to clinical referral by the relevant mental health service Demonstrates capacity and willing to give informed consent Female participants willing to have a pregnancy test before treatment Currently unmedicated with antipsychotic medication Exclusion Criteria: Major physical illness Prior history of intolerance to glyceryl trinitrate Homicidal or suicidal Pregnant or breast feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Morrison, MRCPsych
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
South London and Maudsley
City
London
ZIP/Postal Code
SW9 9NT
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32436761
Citation
Merritt K, Catalan A, Cowley S, Demjaha A, Taylor M, McGuire P, Cooper R, Morrison P. Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study. J Psychopharmacol. 2020 Aug;34(8):839-847. doi: 10.1177/0269881120922967. Epub 2020 May 21.
Results Reference
derived

Learn more about this trial

The Role of Nitric Oxide in Cognition in Schizophrenia

We'll reach out to this number within 24 hrs